1. Home
  2. News

【KBIC Company Topic】Global Korean Company Celltrion, Inc. to start a partnership with Kobe Biomedical Innovation Cluster to promote Korean Startups’ Business Development in Japan and Around the World

February 21, 2024

We are pleased to announce that Celltrion, Inc., a biotechnology company from the Republic of Korea, which has demonstrated a new business paradigm through the development of the world's first antibody biosimilar, has opened its first Japan office in Kobe Biomedical Innovation Cluster (KBIC) collaborating in the activities to support Korean startups to develop their business in KBIC. Celltrion will actively promote Korean startup by multiple activities such as participating in the startup support program “Kansai Life Science Accelerator Program (KLSAP)” as sponsor company, facilitating business matching and networking for Korean startups with KBIC companies and by hosting event for Korean and Japanese startups in KBIC. Having physical base in KBIC, we hope that Celltrion will be able to accelerate their startup support activities by leveraging KBIC life science ecosystem.

【Comment from Sooyoung Lee, Executive Vice President, Head of New Drug Research Division, Celltrion, Inc.】

We are very pleased to be the first Korean biotech/pharmaceutical company to open a new location in Kobe Biomedical Innovation Cluster. We established our business as a startup in 2002 and today we have grown to become one of a leading company in Korean biotech/pharmaceutical industry. Based on our experience, we are accelerating the development of new drugs through open innovation with domestic and international startups with superior technological capabilities.

We believe that the opening of the KBIC office is the first step toward innovative cooperation between our company and Japanese startups. Through Celltrion KBIC office, we hope to frequently meet and interact with many Japanese startups who wish to cooperate with us.

【About Celltrion, Inc.】

Celltrion, Inc. is engaged primarily in the development and production of antibody drugs for the treatment of tumors and autoimmune diseases, based on biotechnology and animal cell mass culture technology. In addition, the company actively utilizes the candidate substance development and selection technologies, cell line development and process development technologies that it has cultivated over the years to independently or jointly develop various new antibody drugs.

In addition, from 2023, we are participating as a supporting partner in the "Kansai Life Science Accelerator Program (KLSAP)", an accelerator program designed to support the overseas expansion of startups in the life science field.

Web: https://www.celltrion.com/en-us

【Contact Information】

Celltrion, Inc.
Soyong Jang
*Replace[at] with @

【Kansai Life Science Accelerator Program (KLSAP)】

KLSAP is an accelerator program sponsored by City of Kobe and Foundation for Biomedical Research and Innovation at Kobe (FBRI) with the aim of fostering and supporting entrepreneurs and managers in the life science field and contributing to the startup ecosystem in the Kobe, Kansai region. The program is supported by life science companies and supporting organizations, and Celltrion, Inc. has been participating in the program as a sponsoring partner since 2023.

KLSAP strongly promote startups in their efforts to develop overseas markets and expand their businesses by providing the opportunity to receive quality advise from experts in the life science business in U.S.